N16 Discontinuation of anti-TNF therapy in patients with inflammatory bowel disease in remission: a qualitative study on shared decision making and patients perspective

S Nabibaks,M Devillers,A de Vries

DOI: https://doi.org/10.1093/ecco-jcc/jjad212.1388

2024-01-01

Journal of Crohn's and Colitis

Abstract:Abstract Background Anti-tumor necrosis factor (TNF) therapy has been the mainstay for managing patients with moderate to severe inflammatory bowel diseases (IBD). Despite its effectiveness, anti-TNF therapy is associated with several side effects such as infections and infusion reactions, as well as considerable costs. Discontinuation of therapy may be considered in patients in long-term remission. Since prediction of the risk of relapse for an individual patient is difficult, shared decision making (SDM) on this decision is highly essential. The aim of this qualitative study is to explore the considerations of IBD patients in remission concerning the decision on discontinuation of anti-TNF therapy. Methods This is an explorative, single center study. Semi-structured interviews were conducted in adult IBD patients in clinical remission, after discontinuation of the anti-TNF therapy as treatment option was discussed by the patient and their treating gastroenterologist. Patients were identified by purposive sampling. Interviews were performed at the outpatient clinic or by telephone. The interviews were recorded, transcribed verbatim and thematically analyzed. Patients were interviewed until saturation was reached. Results Twelve patients were interviewed; age 25-79 years, 7 (58%) males, 7 CD and 5 UC. The duration of the anti-TNF treatment varied from 6 to 16 years. Seven patients were on first-line biological therapy, while 5 were on second or third-line biological therapy. With regard to the therapy decision, 5 patients decided to discontinue their anti-TNF treatment and 7 continued. Three main themes were identified in the interviews: patient considerations regarding the decision, patient education and perceived support of the physician. Key factors influencing decisions included the fear of relapse, with personal impact often prioritized over quantifying the risk. The memory of a previous ‘traumatizing period’ discouraged discontinuation. Notably, some patients were unaware of the efficacy of restarting anti-TNF therapy and alternative options in case of treatment failure. The study highlighted patients’ high appreciation for the support provided by gastroenterologists during the shared decision-making process. Conclusion Since considerations on discontinuation of anti-TNF therapy are diverse among patients, a thorough exploration of fears and impact of a relapse on the personal life is essential during the shared decision making process. Patient education on the therapeutic options in case of relapse is essential to reach a well-considered decision.

gastroenterology & hepatology